New publications:
February 2026:
A review about multiple signaling pathways tightly regulating EMT and MET reversible dynamics and contributing to cell plasticity in prostate carcinogenesis, and prostate cancer progression: here
November 2025:
Deep phenotyping of prostate cancer reveal molecular stratifiers associated with risk of developing metastases: here
October 2025:
An ATLAS of molecular stratifiers for prognostication of treatment response in prostate cancer patients. “We find for the first time that prostate cancer transcriptome signatures predict survival benefit from docetaxel, enabling better treatment selection for patients.” And in general… “Tumor transcriptome-wide expression signatures are biologically and clinically informative”.
This is a novel way to interpret the biology of tumors beyond DNA-based analysis.
Our Persist signature carries prognostic value in M1 disease. Interesting biology to dig in!
August 2025
A first in vitro demo on how to use BET bromodomain inhibitors as radiosensitizers for metastatic prostate cancer by combining with radiopharmaceuticals. More work to be done but this is an amazing result paving the way for new therapeutic approaches for castrate resistant disease .
July 2025:
Potential effects of HDAC inhibitors in metastatic prostate cancer.
Preprints:
A new androgen receptor coregulator: here
Chromatin accessibility of landscape of prostate and prostate cancer: here